Copyright Reports & Markets. All rights reserved.

Global Peptide CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Peptide CDMO by Type
    • 1.3.1 Overview: Global Peptide CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Peptide CDMO Consumption Value Market Share by Type in 2025
    • 1.3.3 APIs and Intermediates
    • 1.3.4 FDF
  • 1.4 Global Peptide CDMO Market by Application
    • 1.4.1 Overview: Global Peptide CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Commercial
    • 1.4.3 Academic Research
    • 1.4.4 Other
  • 1.5 Global Peptide CDMO Market Size & Forecast
  • 1.6 Global Peptide CDMO Market Size and Forecast by Region
    • 1.6.1 Global Peptide CDMO Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Peptide CDMO Market Size by Region, (2021-2032)
    • 1.6.3 North America Peptide CDMO Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Peptide CDMO Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Peptide CDMO Market Size and Prospect (2021-2032)
    • 1.6.6 South America Peptide CDMO Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Peptide CDMO Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Bachem
    • 2.1.1 Bachem Details
    • 2.1.2 Bachem Major Business
    • 2.1.3 Bachem Peptide CDMO Product and Solutions
    • 2.1.4 Bachem Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Bachem Recent Developments and Future Plans
  • 2.2 PolyPeptide
    • 2.2.1 PolyPeptide Details
    • 2.2.2 PolyPeptide Major Business
    • 2.2.3 PolyPeptide Peptide CDMO Product and Solutions
    • 2.2.4 PolyPeptide Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 PolyPeptide Recent Developments and Future Plans
  • 2.3 CordenPharma
    • 2.3.1 CordenPharma Details
    • 2.3.2 CordenPharma Major Business
    • 2.3.3 CordenPharma Peptide CDMO Product and Solutions
    • 2.3.4 CordenPharma Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 CordenPharma Recent Developments and Future Plans
  • 2.4 AmbioPharm
    • 2.4.1 AmbioPharm Details
    • 2.4.2 AmbioPharm Major Business
    • 2.4.3 AmbioPharm Peptide CDMO Product and Solutions
    • 2.4.4 AmbioPharm Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 AmbioPharm Recent Developments and Future Plans
  • 2.5 USV Peptides
    • 2.5.1 USV Peptides Details
    • 2.5.2 USV Peptides Major Business
    • 2.5.3 USV Peptides Peptide CDMO Product and Solutions
    • 2.5.4 USV Peptides Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 USV Peptides Recent Developments and Future Plans
  • 2.6 Thermofischer
    • 2.6.1 Thermofischer Details
    • 2.6.2 Thermofischer Major Business
    • 2.6.3 Thermofischer Peptide CDMO Product and Solutions
    • 2.6.4 Thermofischer Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Thermofischer Recent Developments and Future Plans
  • 2.7 Bio Basic
    • 2.7.1 Bio Basic Details
    • 2.7.2 Bio Basic Major Business
    • 2.7.3 Bio Basic Peptide CDMO Product and Solutions
    • 2.7.4 Bio Basic Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Bio Basic Recent Developments and Future Plans
  • 2.8 JPT
    • 2.8.1 JPT Details
    • 2.8.2 JPT Major Business
    • 2.8.3 JPT Peptide CDMO Product and Solutions
    • 2.8.4 JPT Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 JPT Recent Developments and Future Plans
  • 2.9 Genscript
    • 2.9.1 Genscript Details
    • 2.9.2 Genscript Major Business
    • 2.9.3 Genscript Peptide CDMO Product and Solutions
    • 2.9.4 Genscript Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Genscript Recent Developments and Future Plans
  • 2.10 Xinbang Pharma
    • 2.10.1 Xinbang Pharma Details
    • 2.10.2 Xinbang Pharma Major Business
    • 2.10.3 Xinbang Pharma Peptide CDMO Product and Solutions
    • 2.10.4 Xinbang Pharma Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Xinbang Pharma Recent Developments and Future Plans
  • 2.11 ScinoPharm
    • 2.11.1 ScinoPharm Details
    • 2.11.2 ScinoPharm Major Business
    • 2.11.3 ScinoPharm Peptide CDMO Product and Solutions
    • 2.11.4 ScinoPharm Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 ScinoPharm Recent Developments and Future Plans
  • 2.12 SN Biopharm
    • 2.12.1 SN Biopharm Details
    • 2.12.2 SN Biopharm Major Business
    • 2.12.3 SN Biopharm Peptide CDMO Product and Solutions
    • 2.12.4 SN Biopharm Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 SN Biopharm Recent Developments and Future Plans
  • 2.13 CBL
    • 2.13.1 CBL Details
    • 2.13.2 CBL Major Business
    • 2.13.3 CBL Peptide CDMO Product and Solutions
    • 2.13.4 CBL Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 CBL Recent Developments and Future Plans
  • 2.14 Piramal Pharma
    • 2.14.1 Piramal Pharma Details
    • 2.14.2 Piramal Pharma Major Business
    • 2.14.3 Piramal Pharma Peptide CDMO Product and Solutions
    • 2.14.4 Piramal Pharma Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Piramal Pharma Recent Developments and Future Plans
  • 2.15 CPC Scientific
    • 2.15.1 CPC Scientific Details
    • 2.15.2 CPC Scientific Major Business
    • 2.15.3 CPC Scientific Peptide CDMO Product and Solutions
    • 2.15.4 CPC Scientific Peptide CDMO Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 CPC Scientific Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Peptide CDMO Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Peptide CDMO by Company Revenue
    • 3.2.2 Top 3 Peptide CDMO Players Market Share in 2025
    • 3.2.3 Top 6 Peptide CDMO Players Market Share in 2025
  • 3.3 Peptide CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Peptide CDMO Market: Region Footprint
    • 3.3.2 Peptide CDMO Market: Company Product Type Footprint
    • 3.3.3 Peptide CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Peptide CDMO Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Peptide CDMO Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Peptide CDMO Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Peptide CDMO Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Peptide CDMO Consumption Value by Type (2021-2032)
  • 6.2 North America Peptide CDMO Market Size by Application (2021-2032)
  • 6.3 North America Peptide CDMO Market Size by Country
    • 6.3.1 North America Peptide CDMO Consumption Value by Country (2021-2032)
    • 6.3.2 United States Peptide CDMO Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Peptide CDMO Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Peptide CDMO Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Peptide CDMO Consumption Value by Type (2021-2032)
  • 7.2 Europe Peptide CDMO Consumption Value by Application (2021-2032)
  • 7.3 Europe Peptide CDMO Market Size by Country
    • 7.3.1 Europe Peptide CDMO Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Peptide CDMO Market Size and Forecast (2021-2032)
    • 7.3.3 France Peptide CDMO Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Peptide CDMO Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Peptide CDMO Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Peptide CDMO Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Peptide CDMO Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Peptide CDMO Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Peptide CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Peptide CDMO Consumption Value by Region (2021-2032)
    • 8.3.2 China Peptide CDMO Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Peptide CDMO Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Peptide CDMO Market Size and Forecast (2021-2032)
    • 8.3.5 India Peptide CDMO Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Peptide CDMO Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Peptide CDMO Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Peptide CDMO Consumption Value by Type (2021-2032)
  • 9.2 South America Peptide CDMO Consumption Value by Application (2021-2032)
  • 9.3 South America Peptide CDMO Market Size by Country
    • 9.3.1 South America Peptide CDMO Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Peptide CDMO Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Peptide CDMO Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Peptide CDMO Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Peptide CDMO Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Peptide CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Peptide CDMO Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Peptide CDMO Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Peptide CDMO Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Peptide CDMO Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Peptide CDMO Market Drivers
  • 11.2 Peptide CDMO Market Restraints
  • 11.3 Peptide CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Peptide CDMO Industry Chain
  • 12.2 Peptide CDMO Upstream Analysis
  • 12.3 Peptide CDMO Midstream Analysis
  • 12.4 Peptide CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Peptide CDMO market size was valued at US$ 4944 million in 2025 and is forecast to a readjusted size of US$ 12710 million by 2032 with a CAGR of 14.6% during review period.
    Peptides are synthesized by coupling the carboxyl group of one amino acid to the amino group of another amino acid molecule. Due to the possibility of unintended reactions, protecting groups are common necessary. Chemical peptide synthesis most commonly starts at the carboxyl end of the peptide, and thus progress toward the amino-terminus. This is the opposite direction of protein biosynthesis. A contract development and manufacturing company (CDMO) is a company within the pharmaceutical industry that provides drug development and manufacturing services. Pharmaceutical companies partner with CDMOs as a way to outsource drug development and drug manufacturing. CDMO peptides production via contract peptide manufacturing is to optimize process development and achieve highly efficient conversion at every amino acid coupling to produce a high-purity crude synthetic custom peptide and minimize the demands on downstream processing.
    The Peptide CDMO (Contract Development and Manufacturing Organization) market is driven by the increasing demand for peptide-based therapeutics. Peptides are gaining significant traction in the pharmaceutical industry due to their high specificity, targeted action, and fewer side effects compared to traditional small-molecule drugs. As a result, there is growing interest in developing and manufacturing peptides for a wide range of indications, including oncology, diabetes, cardiovascular diseases, and neurological disorders. This shift is coupled with the rise in personalized medicine, where peptides are seen as promising candidates for tailored therapies. Peptide CDMOs are playing a crucial role by providing specialized services like synthesis, purification, and formulation, enabling pharmaceutical companies to bring peptide-based drugs to market faster and more efficiently. Additionally, advancements in peptide synthesis technologies and the increasing outsourcing trend by biopharmaceutical companies are fueling growth in this sector.
    Despite the positive growth drivers, the Peptide CDMO market faces several challenges. One of the main hurdles is the complexity involved in peptide synthesis and manufacturing, particularly for large-scale production. Peptides are often fragile and prone to degradation, requiring strict control over production processes, which can be both time-consuming and costly. Additionally, the high costs of peptide synthesis, purification, and formulation pose significant barriers to entry for smaller players, limiting competition and innovation in the market. Furthermore, regulatory challenges are a concern, as peptides often face more stringent requirements during the clinical development and commercialization stages compared to traditional small-molecule drugs. These challenges can result in delays in drug development and increased production costs, which could ultimately impact the profitability of peptide CDMOs.
    Global key peptide CDMO producers include Bachem, PolyPeptide, CordenPharma, and others. The top five manufacturers together account for 40% of the market share, with the largest manufacturer being Bachem with 17%. At the sales level, North America is the largest sales market with a market share of over 50%, followed by Europe and China with 33% and 9% respectively.
    This report is a detailed and comprehensive analysis for global Peptide CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Peptide CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Peptide CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Peptide CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Peptide CDMO market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Peptide CDMO
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Peptide CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Peptide CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    APIs and Intermediates
    FDF
    Market segment by Application
    Commercial
    Academic Research
    Other
    Market segment by players, this report covers
    Bachem
    PolyPeptide
    CordenPharma
    AmbioPharm
    USV Peptides
    Thermofischer
    Bio Basic
    JPT
    Genscript
    Xinbang Pharma
    ScinoPharm
    SN Biopharm
    CBL
    Piramal Pharma
    CPC Scientific
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Peptide CDMO product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Peptide CDMO, with revenue, gross margin, and global market share of Peptide CDMO from 2021 to 2026.
    Chapter 3, the Peptide CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Peptide CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide CDMO.
    Chapter 13, to describe Peptide CDMO research findings and conclusion.

    Buy now